Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Execution of an MOU for the Transfer of KYORIN Pharmaceutical's Generic Drug Businesses to a Newly Established JV by Daito and Two Other Companies
Notice Regarding the Status and Completion of Purchase of Own Shares
Daito Pharma snaps 2-session slide on raised profit guidance for year to May 2026, driven by higher formulation ratio
Notice Regarding Revision of Earnings Forecasts
Nine Months, Fiscal Year Ending May 2026 Financial Results Presentation Materials
[Summary] Summary of Consolidated Financial Results for the Nine Months Ended February 28, 2026 (Under Japanese GAAP)
Daito Pharma, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 17%
artience rebounds on subsidiary's partnership agreement with Daito Pharma
Notice Regarding Repurchase of Own Shares
Notice Regarding Repurchase of Own Shares
Notice Regarding Repurchase of Own Shares
(Correction) Partial Correction to “Second Half, Fiscal Year Ending May 2026 Financial Results Presentation Materials”
Summary of Consolidated Financial Results for the Six Months Ended November 30, 2025 (Under Japanese GAAP)
Second Half, Fiscal Year Ending May 2026 Financial Results Presentation Materials
Daito Pharma, First Half Ordinary Profit Increases by 20%, Sep-Nov Ordinary Profit Increases by 46%
Notice Regarding Repurchase of Own Shares
Notice Regarding Repurchase of Own Shares
Notice Regarding Repurchase of Own Shares
Notice Regarding the Results and Completion of the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Transaction (ToSTNeT-3)
1Q Fiscal Year Ending May 2026 Financial Results